Lung Cancer Insights: What’s New in the Field – January Update

This January update summarises recent international advances in lung cancer research, spanning unresectable stage III NSCLC management, screening challenges in never-smokers, novel targeted agents for HER2-altered disease, ferroptosis-based therapeutic strategies, and key developments in ALK-positive first-line therapy, screening eligibility modelling, polygenic risk prediction, and lung cancer mortality trends in Europe.